Welcome to our dedicated page for ADMA BIOLOGICS SEC filings (Ticker: ADMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ADMA BIOLOGICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ADMA BIOLOGICS's regulatory disclosures and financial reporting.
State Street Corporation and its affiliate SSGA Funds Management, Inc. report significant passive ownership of ADMA Biologics common stock as of June 30, 2026. State Street beneficially owned 17,116,022 shares, representing 7.4% of the common stock, with 16,375,576 shares subject to shared voting power and all 17,116,022 shares subject to shared dispositive power; they report no sole voting or dispositive power. Within this, SSGA Funds Management beneficially owned 11,593,203 shares, or 5% of the class, all on a shared voting and dispositive basis. The filing identifies several State Street Global Advisors entities as investment adviser subsidiaries through which the holdings are managed and states that no other person is known to have rights to more than 5% of the dividends or sale proceeds for these securities.
ADMA Biologics reported second quarter 2026 results showing modest top-line growth but significantly higher profitability, driven by ASCENIV. Total revenue for the quarter ended June 30, 2026 was $124.4 million, up 2% year-over-year. ASCENIV revenue rose to $102.9 million, a 24% increase, while revenue from another immune globulin product declined 49% year-over-year but improved sequentially from first-quarter trough levels. Gross profit was $86.3 million with a 69% gross margin, compared with 55% a year earlier, reflecting a richer ASCENIV mix and a yield‑enhanced manufacturing process.
GAAP net income for the quarter was $37.8 million and GAAP basic EPS was $0.17, up 11% and 17% year-over-year, respectively. Adjusted net income was $39.0 million and Adjusted EBITDA $61.8 million, up 8% and 22% year-over-year. For the first half of 2026, revenue was $238.9 million; GAAP net income was $83.1 million and Adjusted EBITDA $121.5 million. Cash and cash equivalents increased to $136.0 million at June 30, 2026, supported by $87.8 million of net cash provided by operating activities, alongside substantial share repurchases and higher long‑term debt. The company reiterated its FY2026 financial guidance and highlighted real‑world data from 127 ASCENIV‑treated patients showing reduced infection‑related hospitalizations and healthcare utilization.
ADMA Biologics executive Kaitlin M. Kestenberg-Messina, COO and SVP, Compliance, reported a tax-withholding disposition of 3,177 shares of common stock at $8.37 per share to satisfy mandatory taxes on vested RSUs. This was not an open-market sale. After the transaction she directly owned 443,061 shares, in addition to multiple unvested RSU grants that will settle into common stock as they vest.
ADMA Biologics CFO and Treasurer Terry Kohler received equity awards on July 16, 2026. He was granted 85,130 restricted stock units (RSUs) that vest over four years, bringing his unvested RSUs to 143,149, including 58,019 from a December 8, 2025 grant. He also received a stock option for 136,363 shares of common stock at an exercise price of $8.81 per share, vesting 25% after one year and the remainder in substantially equal monthly installments through July 16, 2030, with an expiration date of July 16, 2036.
ADMA Biologics, Inc. reported voting results from its 2026 Annual Meeting of Stockholders held on June 2, 2026. As of the April 8, 2026 record date, 232,324,283 common shares were outstanding, and 199,267,547 shares were represented virtually or by proxy, constituting a quorum.
Stockholders elected Class I directors Alison C. Finger and Eduardo Rene Salas. Finger received 156,849,830 votes for and 19,376,842 votes withheld, with 23,040,875 broker non-votes. Salas received 171,947,523 votes for and 4,279,149 votes withheld, with the same broker non-votes.
Stockholders also ratified the appointment of KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026, with 198,655,040 votes for, 329,056 against, and 283,451 abstentions. On a non-binding advisory basis, the Say-on-Pay proposal for named executive officer compensation was approved, receiving 168,169,866 votes for, 7,730,690 against, 326,116 abstentions, and 23,040,875 broker non-votes.
ADMA Biologics director Jerrold B. Grossman reported buying 6,400 shares of common stock at $7.91 per share in an open-market transaction on May 27, 2026. Following this purchase, his directly held position, including 10,690 restricted stock units and 509,594 common shares, totaled 520,284 shares.
He also reported indirect holdings of ADMA common stock through several related entities and relationships: 175 shares held by Brookwood LLC, 38,294 shares held by the Jerrold Grossman 2019 Irrevocable Trust, 31,381 shares held by Genesis Foundation Inc., and 22,857 shares held by his wife.
ADMA Biologics director Jerrold B. Grossman bought additional shares of company stock. On May 12, 2026, he made an open-market purchase of 12,500 shares of ADMA common stock at $8.01 per share. Following this transaction, he directly holds 513,884 common shares, which includes 10,690 RSUs granted on February 9, 2026 that vest in two equal installments on August 9, 2026 and February 9, 2027, along with 503,194 owned shares. He also has several indirect holdings: 175 shares through Brookwood LLC, 38,294 shares through the Jerrold Grossman 2019 Irrevocable Trust, 31,381 shares held by Genesis Foundation Inc., and 22,857 shares owned by his wife.
ADMA Biologics director Jerrold B. Grossman bought 12,500 shares of common stock in an open-market transaction at $8.01 per share. Following this purchase, his directly owned stake shown in the filing increased to 501,384 shares of ADMA common stock.
The filing also lists additional ADMA shares held indirectly through Brookwood LLC, the Jerrold Grossman 2019 Irrevocable Trust, Genesis Foundation Inc., and his wife, reflecting interests associated with the director beyond his direct holdings.
ADMA Biologics reported strong profitability on flat revenue for the quarter ended March 31, 2026. Total revenue was $114.5 million, essentially unchanged year over year, but product mix shifted sharply. ASCENIV sales rose to $97.5 million, up 27.7%, while other IVIG and intermediates declined.
Gross profit increased to $80.8 million and gross margin expanded significantly, helped by ASCENIV growth and the new yield‑enhanced manufacturing process. Net income rose to $45.3 million, compared with $26.9 million a year earlier, with diluted EPS of $0.19.
ADMA used leverage to fund capital returns. It drew $125.0 million on its JPM revolving facility and repurchased 6.8 million shares for $111.1 million, including an accelerated share repurchase. Cash ended at $138.2 million, while total debt increased to $196.9 million.
The company also sold three plasma centers for $12.0 million, recognizing about $8.0 million gain, and later obtained FDA approval to expand ASCENIV’s label to children two years and older.